Latest
China Assets · Parkinson’s Disease
¥84.2 Million, 84 Centers, $328 Million: Hengrui Took a Drug With No Story All the Way to Filing
HRG2010, Hengrui’s carbidopa/levodopa IR/ER capsule for Parkinson’s motor fluctuations, never made the company’s launch forecast or pipeline appendix — yet quietly finished Phase 3 across 84 centers and had its marketing application accepted on August 24, 2026.
China Pharma Majors · Global Asset ReviewSHR-1819 Files for Approval: The Sixth Ticket In
Hengrui’s anti-IL-4Rα antibody has just had its marketing application accepted, with both co-primary endpoints met in Phase 3. But five domestic rivals against the same target are already ahead of it — and the queue ahead holds at least four still under review.